BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34411029)

  • 1. SOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia.
    Chapel DB; Hirsch MS
    Am J Surg Pathol; 2022 Feb; 46(2):213-219. PubMed ID: 34411029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma.
    Chapel DB; Husain AN; Krausz T; McGregor SM
    Am J Surg Pathol; 2017 Dec; 41(12):1675-1682. PubMed ID: 28877056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SOX6 is a Novel Immunohistochemical Marker for Differential Diagnosis of Epithelioid Mesothelioma From Lung Adenocarcinoma.
    Kambara T; Amatya VJ; Kushitani K; Suzuki R; Fujii Y; Kai Y; Miyata Y; Okada M; Takeshima Y
    Am J Surg Pathol; 2020 Sep; 44(9):1259-1265. PubMed ID: 32496433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.
    Xing D; Banet N; Sharma R; Vang R; Ronnett BM; Illei PB
    Hum Pathol; 2018 Feb; 72():160-166. PubMed ID: 29241740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
    Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
    Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of SOX6 and DAB2 for the Diagnosis of Malignant Mesothelioma.
    Naso JR; Cheung S; Ionescu DN; Churg A
    Am J Surg Pathol; 2021 Sep; 45(9):1245-1251. PubMed ID: 33782226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa?
    Wolsky RJ; Price MA; Zaloudek CJ; Rabban JT
    Int J Gynecol Pathol; 2018 May; 37(3):262-274. PubMed ID: 28700429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
    Comin CE; Saieva C; Messerini L
    Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
    Cigognetti M; Lonardi S; Fisogni S; Balzarini P; Pellegrini V; Tironi A; Bercich L; Bugatti M; Rossi G; Murer B; Barbareschi M; Giuliani S; Cavazza A; Marchetti G; Vermi W; Facchetti F
    Mod Pathol; 2015 Aug; 28(8):1043-57. PubMed ID: 26022455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
    Davidson B
    Hum Pathol; 2016 Dec; 58():123-127. PubMed ID: 27589896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma.
    Devins KM; Zukerberg L; Watkins JC; Hung YP; Oliva E
    Int J Gynecol Pathol; 2023 Mar; 42(2):159-166. PubMed ID: 35512220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
    Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
    Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nongynecologic metastases to fallopian tube mucosa: a potential mimic of tubal high-grade serous carcinoma and benign tubal mucinous metaplasia or nonmucinous hyperplasia.
    Rabban JT; Vohra P; Zaloudek CJ
    Am J Surg Pathol; 2015 Jan; 39(1):35-51. PubMed ID: 25025442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
    Ordóñez NG
    Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
    Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
    J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
    Naso JR; Tsuji S; Churg A
    Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A diagnostic approach to paratesticular lesions with tubulopapillary architecture: a series of 16 serous borderline tumors/low-grade serous carcinoma and 14 well-differentiated papillary mesothelial tumors and mesothelioma.
    Zafar R; Schrader LJ; Cheville JC; Schoolmeester JK; Roden AC; Aubry MC; Yi ES; Raghunathan A; Herrera-Hernandez L; Thompson RH; Boorjian SA; Leibovich BC; Keeney GL; Jimenez RE; Gupta S
    Hum Pathol; 2022 Oct; 128():31-47. PubMed ID: 35809685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update.
    Ordóñez NG
    Adv Anat Pathol; 2006 Jan; 13(1):16-25. PubMed ID: 16462153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas.
    Ordóñez NG
    Mod Pathol; 2013 Apr; 26(4):553-62. PubMed ID: 23196794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis.
    Kurman RJ; Vang R; Junge J; Hannibal CG; Kjaer SK; Shih IeM
    Am J Surg Pathol; 2011 Nov; 35(11):1605-14. PubMed ID: 21997682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.